NCT02573259

Brief Summary

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
147

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Feb 2016

Longer than P75 for phase_1

Geographic Reach
7 countries

67 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 6, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 9, 2015

Completed
4 months until next milestone

Study Start

First participant enrolled

February 10, 2016

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 19, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 19, 2020

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

December 13, 2021

Completed
Last Updated

December 13, 2021

Status Verified

October 1, 2021

Enrollment Period

4.8 years

First QC Date

October 6, 2015

Results QC Date

September 13, 2021

Last Update Submit

October 29, 2021

Conditions

Keywords

efficacysafetypharmacokineticspharmacodynamicsopen labeldose responsemultiple ascending doseimmunogenicityrecommended phase 2 dosesubcutaneous

Outcome Measures

Primary Outcomes (6)

  • Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1

    DLT was defined as any of the following drug-related adverse events (AEs) occurring during the first cycle (21 days for IV dosing, 28 days for SC dosing) in Part 1: Grade 5 AE; Grade 4 neutropenia lasting \>5 days from initiation of granulocyte colony stimulating factor; Grade 4 thrombocytopenia with bleeding; Platelet transfusion requirement or a platelet count \<10,000/uL; Grade 4 non-hematologic AE; Grade 3 AE lasting \>7 days despite optimal supportive care; Grade 3 central nervous system AE regardless of duration; met criteria for drug induced liver injury. Severity of AEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Cycle 1 in Part 1 (21 days for IV administration of PF-06801591; 28 days for SC administration of PF-06801591)

  • Number of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

    AE = any untoward medical occurrence in participant who received study treatment without regard to possibility of causal relationship. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  • Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2

    Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent events = between first dose of study treatment and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Grades of severity were defined by CTCAE v4.03. Grades of severity were defined by CTCAE v4.03. Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  • Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2

    Following parameters were analyzed for laboratory examination: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased); chemistries (increase of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood bilirubin, CPK, creatinine, gamma-glutamyl transferase \[GGT\], lipase, and serum amylase); urinalysis (proteinuria); coagulation (activated partial thromboplastin time prolonged, international normalized ratio \[INR\] increased). Grades of severity were defined by CTCAE v4.03. Grade 0 = No Change from normal or reference range (this grade is not included in the CTCAE v4.03 document but may used in certain circumstances). Grade 1 = mild adverse event (AE). Grade 2 = moderate AE; Grade 3 = severe AE. Grade 4 = life-threatening consequences; urgent intervention indicated. Grade 5 = death related to AE.

    Baseline up to 28 days after last dose of study treatment (maximum of 1634 days)

  • Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2

    ORR was defined as percentage of participants with confirmed objective response (OR) of complete response (CR) and partial response (PR) based on RECIST version 1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

    Baseline up to end of treatment in Part 2 (maximum of 851 days)

  • Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2

    ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.

    Baseline up to end of treatment in Part 2 (maximum of 851 days)

Secondary Outcomes (19)

  • Maximum Plasma Concentration (Cmax) of PF-06801591 - Part 1

    Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  • AUClast of PF-06801591 in Part 1.

    Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1 in Part 1

  • Clearance (CL) of PF-06801591 - Part 1

    Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  • Volume of Distribution at Steady State (Vss) of PF-06801591 - Part 1

    Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1

  • Accumulation Ratio (Rac) of PF-06801591 - Part 1

    Pre-dose and 1 hour post dose on Day 1 of Cycles 1 and 4 in Part 1

  • +14 more secondary outcomes

Study Arms (5)

Arm 1 PF-06801591

EXPERIMENTAL

0.5 mg/kg IV every 21 days (Part 1)

Drug: PF-06801591

Arm 2 PF-06801591

EXPERIMENTAL

1.0 mg/kg IV every 21 days (Part 1)

Drug: PF-06801591

Arm 3 PF-06801591

EXPERIMENTAL

3.0 mg/kg IV every 21 days (Part 1)

Drug: PF-06801591

Arm 4 PF-06801591

EXPERIMENTAL

10 mg/kg IV every 21 days (Part 1)

Drug: PF-06801591

Arm 5 PF-06801591

EXPERIMENTAL

300 mg SC every 28 days (Part 1 and 2)

Drug: PF-06801591

Interventions

IV every 21 days (Part 1)

Arm 1 PF-06801591Arm 2 PF-06801591Arm 3 PF-06801591Arm 4 PF-06801591

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Histological or cytological diagnosis of locally advanced or metastatic NSCLC or urothelial carcinoma who have progressed on or were intolerant to standard of care systemic therapy, or for whom standard of care systemic therapy was refused (refusal must be documented) or unavailable.
  • No prior treatment with anti-PD-1 or anti-PD-L1 therapy.
  • NSCLC patients whose tumor is not known to have ALK or EGFR mutations must have progressed on or after no more than 1 prior line of platinum-containing systemic therapy or were intolerant or refused standard of care systemic therapy.
  • NSCLC patients whose tumor is known to have ALK or EGFR mutation must have received prior systemic therapies that only include 1 or more lines of ALK or EGFR targeting drugs and chemotherapy limited to 1 line of a platinum-based regimen and they must have progressed on or after both types of therapies.
  • Urothelial carcinoma patients must have received up to 2 lines of prior systemic therapy and progressed on or after, experienced disease recurrence within 12 months of neoadjuvant or adjuvant treatment, were intolerant to, ineligible or refused platinum-containing systemic therapy. If urothelial cancer patients are treatment naïve and eligible for platinum-containing systemic therapy but are refusing platinum chemotherapy, they must also be documented to have previous PD-L1 high status.
  • Provide archived tumor tissue sample taken within the past 2 years or provide a fresh tumor biopsy sample.
  • At least one measurable lesion as defined by RECIST version 1.1.
  • Adequate renal, liver, thyroid and bone marrow function.
  • Performance status 0 or 1.
  • Patient is capable of receiving study treatment for at least 8 weeks.

You may not qualify if:

  • Active brain or leptomeningeal metastases.
  • Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy or prior allogeneic bone marrow or hematopoietic stem cell transplant.
  • Patients with a condition requiring systemic treatment with either corticosteroids (\>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses \>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Patients with a history of interstitial lung disease, non-infectious pneumonitis, or active pulmonary tuberculosis. Those with active lung infections requiring treatment are also excluded.
  • History of Grade ≥3 immune mediated AE (including AST/ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co-stimulatory agents, etc.) and required immunosuppressive therapy.
  • Active hepatitis B or C, HIV/AIDS.
  • Other potentially metastatic malignancy within past 5 years.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (67)

Clinical Research Unit

Los Angeles, California, 90024, United States

Location

Ronald Reagan Medical Center, Department of Radiological Sciences

Los Angeles, California, 90095, United States

Location

Ronald Reagan UCLA Medical Center, Drug Information Center

Los Angeles, California, 90095, United States

Location

UCLA Hematology & Oncology Clinic

Los Angeles, California, 90095, United States

Location

Santa Monica UCLA Hematology & Oncology Clinic

Santa Monica, California, 90404, United States

Location

Norton Cancer Institute, Multidisciplinary Clinic

Louisville, Kentucky, 40202, United States

Location

Norton Cancer Institute, Norton Healthcare Pavilion

Louisville, Kentucky, 40202, United States

Location

Norton Hospital

Louisville, Kentucky, 40202, United States

Location

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States

Location

University of Rochester

Rochester, New York, 14642, United States

Location

UNC Hospitals, The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599-7600, United States

Location

Tennessee Oncology, PLLC

Dickson, Tennessee, 37055, United States

Location

Tennessee Oncology, PLLC

Franklin, Tennessee, 37067, United States

Location

Tennessee Oncology, PLLC

Gallatin, Tennessee, 37066, United States

Location

Tennessee Oncology, PLLC

Hermitage, Tennessee, 37076, United States

Location

Tennessee Oncology, PLLC

Lebanon, Tennessee, 37090, United States

Location

Tennessee Oncology, PLLC

Murfreesboro, Tennessee, 37129, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States

Location

The Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37205, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37207, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37211, United States

Location

Tennessee Oncology, PLLC

Shelbyville, Tennessee, 37160, United States

Location

Tennessee Oncology, PLLC

Smyrna, Tennessee, 37167, United States

Location

MHAT Uni Hospital OOD

Panagyurishte, Pazardzhik, 4500, Bulgaria

Location

Complex Oncology Center - Plovdiv EOOD

Plovdiv, 4000, Bulgaria

Location

"MHAT for Women Health - Nadezhda" OOD

Sofia, 1330, Bulgaria

Location

SHATOD "Dr. Marko Antonov Markov - Varna" EOOD

Varna, 9002, Bulgaria

Location

Hospital Sultan Ismail

Johor Bahru, Johor, 81100, Malaysia

Location

University Malaya Medical Centre

Lembah Pantai, Kuala Lumpur, 59100, Malaysia

Location

Hospital Tengku Ampuan Afzan

Kuantan, Pahang, 25100, Malaysia

Location

Clinical Research Centre(Crc), Hospital Umum Sarawak

Kuching, Sarawak, 93586, Malaysia

Location

Szpitale Pomorskie Sp. z.o.o., Oddzial Onkologii i Radioterapii

Gdynia, 81-519, Poland

Location

Regionalny Szpital Specjalistyczny im. dr. Wl. Bieganskiego w Grudziadzu

Grudziądz, 86-300, Poland

Location

Centrum Badan Klinicznych JCI Life Science Park

Krakow, 30-348, Poland

Location

Mazowiecki Szpital Specjalistyczny im. Dr. Jozefa Psarskiego w Ostrolece, Osrodek Onkologiczny

Ostrołęka, 07-410, Poland

Location

Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina

Otwock, 05-400, Poland

Location

Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie

Warsaw, 02-781, Poland

Location

Sbhi "Lrcod"

Vsevolozhsky District, Leningradskaya Oblast', 188663, Russia

Location

SBHI ¨Saint-Petersburg clinical scientific practical center of specialized types of

Pesochny Village, Sankt-Peterburg, 197758, Russia

Location

SBHI "ChRCCO and NM"

Chelyabinsk, 454087, Russia

Location

MROI n.a. P.A. Gertsen, filiation of FSBI "NMRC of radiology" MoH Russia

Moscow, 125284, Russia

Location

BHI of Omsk Region "Clinical Oncology Dispensary"

Omsk, 644013, Russia

Location

Joint Stock Company Current medical technologies

Saint Petersburg, 190013, Russia

Location

Joint-Stock Company Current medical technologies

Saint Petersburg, 190121, Russia

Location

Non-governmental Healthcare Institution ¨Railway Clinical Hospital of JSC ¨Russian Railways¨

Saint Petersburg, 195271, Russia

Location

SPb SBHI "City Clinical Oncology Dispensary"

Saint Petersburg, 197022, Russia

Location

SPb SBHI "City Clinical Oncology Dispensary"

Saint Petersburg, 198255, Russia

Location

SBHI YaR ¨Regional clinical oncology hospital¨

Yaroslavl, 150054, Russia

Location

National Cancer Center

Goyang-si, Gyeonggi-do, 10408, South Korea

Location

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

Location

The Catholic University of Korea, St. Vincent's Hospital

Suwon, Gyeonggi-do, 16247, South Korea

Location

Gachon University Gil Medical Center

Incheon, 21565, South Korea

Location

Division of Medical Oncology, Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea

Location

Severance Hospital Yonsei University Health System

Seoul, 03722, South Korea

Location

Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea

Location

Asan Medical Center

Seoul, 05505, South Korea

Location

Ulsan University Hospital

Ulsan, 44033, South Korea

Location

Communal Non-profit Institution "City Clinical Hospital #4" of Dnipro City Council, Department of

Dnipro, 49102, Ukraine

Location

Communal non-Commercial Enterprise "Prykarpatski Clinical Oncological Center of Ivano-

Ivano-Frankivsk, 79018, Ukraine

Location

Grigoriev Radiological Institute of the National Academy of Medical Sciences of Ukraine,

Kharkiv, 61024, Ukraine

Location

Communal Non-profit Institution of Kharkiv Regional Council "Regional Clinical Specialized Health

Kharkiv, 61166, Ukraine

Location

"Specialized Clinic "Prognosis Optima" LLC

Kyiv, 03126, Ukraine

Location

Communal noncommercial enterprise Sumy regional Rada Sumy regional clinical oncologic dispensary,

Sumy, 40030, Ukraine

Location

Communal Non-profit Institution "Central City Clinical Hospital" of Uzhhorod City Council,

Uzhhorod, 88000, Ukraine

Location

Vinnytsia Regional Clinical Oncological Hospital

Vinnytsia, 21029, Ukraine

Location

Communal Institution ¨Zaporizhzhya Regional Clinical Oncological Dispensary¨

Zaporizhzhya, 69040, Ukraine

Location

Related Publications (3)

  • Sako C, Duan C, Maresca K, Kent S, Schmidt TG, Aerts HJWL, Parikh RB, Simon GR, Jordan P. Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer. JCO Clin Cancer Inform. 2024 Dec;8:e2400133. doi: 10.1200/CCI.24.00133. Epub 2024 Dec 13.

  • Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML. Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Target Oncol. 2021 Nov;16(6):773-787. doi: 10.1007/s11523-021-00833-2. Epub 2021 Oct 25.

  • Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836.

Related Links

MeSH Terms

Conditions

MelanomaSarcomaCarcinoma, Transitional Cell

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue DiseasesNeoplasms, Connective and Soft TissueCarcinomaNeoplasms, Glandular and Epithelial

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 6, 2015

First Posted

October 9, 2015

Study Start

February 10, 2016

Primary Completion

November 19, 2020

Study Completion

November 19, 2020

Last Updated

December 13, 2021

Results First Posted

December 13, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Locations